Why is $ARQT moving today? · SEC 8-K archive

$ARQT SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $ARQT: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $ARQT filing catalyst

Why did $ARQT trigger an AI stock catalyst alert?

$ARQT triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: Arcutis Biotherapeutics Q3 Revenue Up 45% to $143.9M, EPS $0.06, Raises FY26 Guidance. Key points: - Q3 net product revenues reached $143.9M (+45% YoY), driven by strong ZORYVE demand across all formulations. - Net income of $8.8M ($0.06 diluted EPS) vs $7.4M in Q3 2025. - FY26 net product sales guidance raised to $535M–$545M from previous $525M–$540M.

How did $ARQT stock react after the SEC filing?

After the SEC 8-K for $ARQT, observed market reaction: T0 price $34.05. Past moves do not guarantee future results.

Where can I get real-time $ARQT SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $ARQT via Telegram and the VIP Web Terminal from €10/month.

$ARQT

$ARQT – Arcutis Biotherapeutics Q3 Revenue Up 45% to $143.9M, EPS $0.06, Raises FY26 Guidance

Arcutis Biotherapeutics, Inc.

2026-11-04 00:00:00 UTC · SEC 8-K · All $ARQT

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+6.5 / 10)

Q3 net product revenues reached $143.9M (+45% YoY), driven by strong ZORYVE demand across all formulations.
Net income of $8.8M ($0.06 diluted EPS) vs $7.4M in Q3 2025.
FY26 net product sales guidance raised to $535M–$545M from previous $525M–$540M.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →